AnaptysBio Inc

ANAB remains in Stage 3 Distribution with active Support Failure confirming medium-term bearish bias; price holds at the rising 200-day SMA support but short-term conditions are neutral, so further sell-side participation should be deferred into rallies toward the 9/20 EMA and 50 SMA resistance zone.

• ↑$100M stock repurchase may boost share price amid undervaluation
• ↑Revenue of $25.6M topped expectations despite $1.84 EPS loss
• ↓EPS loss of $1.84 underscores weak profitability and cash burn